Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Subgroup analysis of efficacy, safety and QOL in patients who received selinexor/bortez/dexa with and without selinexor dose reduction shows improvements in efficacy, quality of life (QOL) and safety outcomes with dose reduction.”
Title: Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial
Authors: Sosana Delimpasi, Ivan Špička, Jason P. Butler, Don A. Stevens, Mercedes Gironella Mesa, Ceri Bygrave, Giovanni Marino Merlo, Charles la Porte, Meletios A. Dimopoulos
You can read the Full Article in British Journal of Haematology.
You can find other articles featuring Robert Orlowski on OncoDaily.
